HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Upstream Bio (NASDAQ:UPB) with a Buy and maintains $36 price target.
Stocks · News reference
Upstream Bio Announces Phase 3 Plans For Verekitug At 400 mg Every 12 Weeks In Severe Asthma And CRSwNP, With About 1,500 Patients Across Two Placebo-Controlled Trials; On Track To Initiate Q1 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Upstream Bio, Inc. (UPB)
Filed: 2026-09-01 AccNo: 0001193125-26-377485 Size: 238 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9
JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.